gracecastuc080_lung_dr oxnard are patients or payers objecting to repeat biopsy
Published 11 years ago • 25 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
2:22
gracecastuc 124 lung_dr. oxnard on repeat biopsy with acquired resistance targeted therapy
-
2:19
gracecastuc097_lung_dr. oxnard on most promising targeted therapy
-
1:59:57
grace - global resource for advancing cancer education live stream
-
3:58
gracecastuc-009_ca-101_do we need to do repeat biopsies with disease progression?
-
1:09
gracecastuc-037_lung_repeat biopsy at initial diag. or with acqd. resistance to a targeted therapy?
-
0:13
the importance of biomarker testing- targeted therapies in lung cancer 2023- #shorts #youtubeshorts
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
2:58
gracecastuc-068_lung_dr. oxnard on what molecular markers to test for in advanced nsclc
-
6:42
maintenance systemic therapy: the nrg-lu trial - onctalk lung 2023
-
0:31
biomarkers in nsclc - targeted therapies in lung cancer 2023 - #youtubeshorts #shorts
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
5:42
gracecastuc-006 - which patients with advanced lung cancer should potentially receive local therapy?
-
5:56
biopsies in lung cancer: tumor vs. liquid - lcvl 2024
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
3:10
gracecastuc-062_lung_dr. spigel: we've probably made maint. therapy more complicated than necessary
-
5:34
gracecastuc-038_lung_managing acq. resistance to egfr therapy (and probably crizotinib, too)
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?